# CINRYZE as a Donor Pre-treatment Strategy in Kidney Recipients of KDPI>60%

> **NCT02435732** · PHASE1 · UNKNOWN · sponsor: **University of Wisconsin, Madison** · enrollment: 72 (estimated)

## Conditions studied

- Kidney Failure

## Interventions

- **DRUG:** Placebo saline solution
- **DRUG:** Heparin
- **DRUG:** CINRYZE

## Key facts

- **NCT ID:** NCT02435732
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12
- **Primary completion:** 2021-05
- **Final completion:** 2022-05
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2020-10-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02435732

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02435732, "CINRYZE as a Donor Pre-treatment Strategy in Kidney Recipients of KDPI>60%". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02435732. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*